Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cocrystal Pharma ( (COCP) ) has shared an announcement.
On December 18, 2025, Cocrystal Pharma announced that the Institutional Review Board at Emory University School of Medicine approved the initiation of a Phase 1b human challenge study of its oral antiviral candidate CDI-988 for the prevention and treatment of norovirus infections, with subject screening already underway and enrollment planned to begin in the first quarter of 2026. CDI-988, designed as a broad-spectrum inhibitor targeting a conserved region of the norovirus 3CL protease and previously shown in August 2025 to have favorable Phase 1 safety and tolerability data, will be tested in a randomized, double-blind, placebo-controlled trial of up to 40 healthy adults to assess efficacy in reducing clinical symptoms, viral shedding and disease severity, as well as safety and pharmacokinetics; the program underscores Cocrystal’s bid to address a major unmet medical need in norovirus, where no approved treatments or vaccines exist despite substantial global health and economic burdens.
The most recent analyst rating on (COCP) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Cocrystal Pharma stock, see the COCP Stock Forecast page.
Spark’s Take on COCP Stock
According to Spark, TipRanks’ AI Analyst, COCP is a Underperform.
Cocrystal Pharma faces significant financial challenges, with no revenue and ongoing operational losses severely affecting its stock score. The technical analysis indicates potential downward pressure, while the negative valuation metrics are concerning. However, recent corporate events provide some positive aspects, suggesting future growth potential. Overall, the company’s stock score reflects these mixed factors, indicating substantial risk with some long-term opportunities.
To see Spark’s full report on COCP stock, click here.
More about Cocrystal Pharma
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company developing novel antiviral therapeutics that target viral replication processes in influenza, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C. Using a proprietary structure-based drug discovery platform that combines structural biology, enzymology and medicinal chemistry, the company focuses on creating broad-spectrum antiviral drugs for acute, chronic and potentially pandemic viral diseases.
Average Trading Volume: 174,979
Technical Sentiment Signal: Strong Sell
Current Market Cap: $13.56M
See more data about COCP stock on TipRanks’ Stock Analysis page.